Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer
Robert I. Haddad(Broad Institute), Roy B. Tishler(Dana-Farber Cancer Institute), Lori J. Wirth(Harvard University), Stephen T. Sonis(Brigham and Women's Hospital), Jayme Flynn(Dana-Farber Cancer Institute), Patricia Braschayko(Dana-Farber Cancer Institute), Aaron M. Allen(Tel Aviv University), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), Yi Li(Dana-Farber Cancer Institute), Anand Mahadevan(Geisinger Medical Center), Rosemary Costello(Dana-Farber Cancer Institute), Elaine Burke(St Thomas' Hospital)
Cited by 98
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926